Emerging targets for drug addiction treatment /:
In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid a...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Hauppauge, N.Y. :
Nova Science Publisher's,
2012.
|
| Schriftenreihe: | Substance abuse assessment, interventions and treatment series.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t. |
| Beschreibung: | Includes bibliographical references and index. |
| Beschreibung: | 1 online resource |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781620819548 1620819546 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1162056565 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 120628s2012 nyua ob 001 0 eng | ||
| 010 | |a 2020686392 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d OCLCF |d VLY |d OCLCO |d EBLCP |d N$T |d YDXCP |d E7B |d DEBSZ |d AGLDB |d YDX |d VTS |d STF |d M8D |d OCLCO |d OCLCQ |d OCLCO |d OCLCL |d TMA |d OCLCQ | ||
| 019 | |a 834136709 |a 898103608 |a 962312708 |a 1001911024 |a 1264839167 |a 1297222578 |a 1297383880 | ||
| 020 | |a 9781620819548 |q ebook | ||
| 020 | |a 1620819546 | ||
| 020 | |z 9781620819135 |q hardcover | ||
| 020 | |z 1620819139 | ||
| 035 | |a (OCoLC)1162056565 |z (OCoLC)834136709 |z (OCoLC)898103608 |z (OCoLC)962312708 |z (OCoLC)1001911024 |z (OCoLC)1264839167 |z (OCoLC)1297222578 |z (OCoLC)1297383880 | ||
| 050 | 0 | 0 | |a RC563 |
| 072 | 7 | |a PSY |x 038000 |2 bisacsh | |
| 072 | 7 | |a SEL |x 026000 |2 bisacsh | |
| 082 | 7 | |a 362.29 |2 23 | |
| 084 | |a 44.38 |2 bcl | ||
| 084 | |a 15,3 |2 ssgn | ||
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Emerging targets for drug addiction treatment / |c editor, Juan Canales. |
| 264 | 1 | |a Hauppauge, N.Y. : |b Nova Science Publisher's, |c 2012. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Substance abuse assessment, interventions and treatment | |
| 500 | |a Includes bibliographical references and index. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) | |
| 505 | 8 | |a 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy | |
| 505 | 8 | |a 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES | |
| 505 | 8 | |a 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES | |
| 505 | 8 | |a Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES | |
| 520 | |a In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Drug addiction |x Treatment. |0 http://id.loc.gov/authorities/subjects/sh85089813 | |
| 650 | 6 | |a Toxicomanie |x Traitement. | |
| 650 | 7 | |a PSYCHOLOGY |x Psychopathology |x Addiction. |2 bisacsh | |
| 650 | 7 | |a SELF-HELP |x Substance Abuse & Addictions |x General. |2 bisacsh | |
| 650 | 7 | |a Drug addiction |x Treatment |2 fast | |
| 650 | 7 | |a Drogenabhängigkeit |2 gnd | |
| 650 | 7 | |a Pharmakotherapie |2 gnd |0 http://d-nb.info/gnd/4076066-2 | |
| 650 | 7 | |a Arzneimittelentwicklung |2 gnd | |
| 700 | 1 | |a Canales, Juan. | |
| 758 | |i has work: |a Emerging Targets for Drug Addiction Treatment (Text) |1 https://id.oclc.org/worldcat/entity/E39PCYGmk4gvrMv8CCYQJjbtVd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Emerging targets for drug addiction treatment |d Hauppauge, N.Y. : Nova Science Publisher's, 2012. |z 9781620819135 (hardcover) |w (DLC) 2012017839 |
| 830 | 0 | |a Substance abuse assessment, interventions and treatment series. |0 http://id.loc.gov/authorities/names/no2009111890 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL1884191 | ||
| 938 | |a ebrary |b EBRY |n ebr10686321 | ||
| 938 | |a EBSCOhost |b EBSC |n 541446 | ||
| 938 | |a YBP Library Services |b YANK |n 9947882 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1162056565 |
|---|---|
| _version_ | 1816882521796771841 |
| adam_text | |
| any_adam_object | |
| author2 | Canales, Juan |
| author2_role | |
| author2_variant | j c jc |
| author_facet | Canales, Juan |
| author_sort | Canales, Juan |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC563 |
| callnumber-raw | RC563 |
| callnumber-search | RC563 |
| callnumber-sort | RC 3563 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES |
| ctrlnum | (OCoLC)1162056565 |
| dewey-full | 362.29 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.29 |
| dewey-search | 362.29 |
| dewey-sort | 3362.29 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06410cam a2200685 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1162056565</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">120628s2012 nyua ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2020686392</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">DLC</subfield><subfield code="d">OCLCF</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">EBLCP</subfield><subfield code="d">N$T</subfield><subfield code="d">YDXCP</subfield><subfield code="d">E7B</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">AGLDB</subfield><subfield code="d">YDX</subfield><subfield code="d">VTS</subfield><subfield code="d">STF</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">TMA</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">834136709</subfield><subfield code="a">898103608</subfield><subfield code="a">962312708</subfield><subfield code="a">1001911024</subfield><subfield code="a">1264839167</subfield><subfield code="a">1297222578</subfield><subfield code="a">1297383880</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781620819548</subfield><subfield code="q">ebook</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1620819546</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781620819135</subfield><subfield code="q">hardcover</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1620819139</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1162056565</subfield><subfield code="z">(OCoLC)834136709</subfield><subfield code="z">(OCoLC)898103608</subfield><subfield code="z">(OCoLC)962312708</subfield><subfield code="z">(OCoLC)1001911024</subfield><subfield code="z">(OCoLC)1264839167</subfield><subfield code="z">(OCoLC)1297222578</subfield><subfield code="z">(OCoLC)1297383880</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RC563</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">PSY</subfield><subfield code="x">038000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">SEL</subfield><subfield code="x">026000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">362.29</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bcl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Emerging targets for drug addiction treatment /</subfield><subfield code="c">editor, Juan Canales.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hauppauge, N.Y. :</subfield><subfield code="b">Nova Science Publisher's,</subfield><subfield code="c">2012.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Substance abuse assessment, interventions and treatment</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug addiction</subfield><subfield code="x">Treatment.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85089813</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Toxicomanie</subfield><subfield code="x">Traitement.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSYCHOLOGY</subfield><subfield code="x">Psychopathology</subfield><subfield code="x">Addiction.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SELF-HELP</subfield><subfield code="x">Substance Abuse & Addictions</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug addiction</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drogenabhängigkeit</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/4076066-2</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canales, Juan.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Emerging Targets for Drug Addiction Treatment (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCYGmk4gvrMv8CCYQJjbtVd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Emerging targets for drug addiction treatment</subfield><subfield code="d">Hauppauge, N.Y. : Nova Science Publisher's, 2012.</subfield><subfield code="z">9781620819135 (hardcover)</subfield><subfield code="w">(DLC) 2012017839</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Substance abuse assessment, interventions and treatment series.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2009111890</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL1884191</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10686321</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">541446</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">9947882</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1162056565 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:29:56Z |
| institution | BVB |
| isbn | 9781620819548 1620819546 |
| language | English |
| lccn | 2020686392 |
| oclc_num | 1162056565 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Nova Science Publisher's, |
| record_format | marc |
| series | Substance abuse assessment, interventions and treatment series. |
| series2 | Substance abuse assessment, interventions and treatment |
| spelling | Emerging targets for drug addiction treatment / editor, Juan Canales. Hauppauge, N.Y. : Nova Science Publisher's, 2012. 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Substance abuse assessment, interventions and treatment Includes bibliographical references and index. EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t. English. Drug addiction Treatment. http://id.loc.gov/authorities/subjects/sh85089813 Toxicomanie Traitement. PSYCHOLOGY Psychopathology Addiction. bisacsh SELF-HELP Substance Abuse & Addictions General. bisacsh Drug addiction Treatment fast Drogenabhängigkeit gnd Pharmakotherapie gnd http://d-nb.info/gnd/4076066-2 Arzneimittelentwicklung gnd Canales, Juan. has work: Emerging Targets for Drug Addiction Treatment (Text) https://id.oclc.org/worldcat/entity/E39PCYGmk4gvrMv8CCYQJjbtVd https://id.oclc.org/worldcat/ontology/hasWork Print version: Emerging targets for drug addiction treatment Hauppauge, N.Y. : Nova Science Publisher's, 2012. 9781620819135 (hardcover) (DLC) 2012017839 Substance abuse assessment, interventions and treatment series. http://id.loc.gov/authorities/names/no2009111890 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446 Volltext |
| spellingShingle | Emerging targets for drug addiction treatment / Substance abuse assessment, interventions and treatment series. EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine) 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES Drug addiction Treatment. http://id.loc.gov/authorities/subjects/sh85089813 Toxicomanie Traitement. PSYCHOLOGY Psychopathology Addiction. bisacsh SELF-HELP Substance Abuse & Addictions General. bisacsh Drug addiction Treatment fast Drogenabhängigkeit gnd Pharmakotherapie gnd http://d-nb.info/gnd/4076066-2 Arzneimittelentwicklung gnd |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85089813 http://d-nb.info/gnd/4076066-2 |
| title | Emerging targets for drug addiction treatment / |
| title_auth | Emerging targets for drug addiction treatment / |
| title_exact_search | Emerging targets for drug addiction treatment / |
| title_full | Emerging targets for drug addiction treatment / editor, Juan Canales. |
| title_fullStr | Emerging targets for drug addiction treatment / editor, Juan Canales. |
| title_full_unstemmed | Emerging targets for drug addiction treatment / editor, Juan Canales. |
| title_short | Emerging targets for drug addiction treatment / |
| title_sort | emerging targets for drug addiction treatment |
| topic | Drug addiction Treatment. http://id.loc.gov/authorities/subjects/sh85089813 Toxicomanie Traitement. PSYCHOLOGY Psychopathology Addiction. bisacsh SELF-HELP Substance Abuse & Addictions General. bisacsh Drug addiction Treatment fast Drogenabhängigkeit gnd Pharmakotherapie gnd http://d-nb.info/gnd/4076066-2 Arzneimittelentwicklung gnd |
| topic_facet | Drug addiction Treatment. Toxicomanie Traitement. PSYCHOLOGY Psychopathology Addiction. SELF-HELP Substance Abuse & Addictions General. Drug addiction Treatment Drogenabhängigkeit Pharmakotherapie Arzneimittelentwicklung |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541446 |
| work_keys_str_mv | AT canalesjuan emergingtargetsfordrugaddictiontreatment |